Palisade Bio Inc

NASDAQ:PALI  
0.52
0.00 (0.00%)
Debt Financing / Related, Earnings Announcements

Palisade Bio Reports Year End 2021 Financial Results

Published: 03/18/2022 13:46 GMT
Palisade Bio Inc (PALI) - Palisade Bio (nasdaq: Pali) Reports Year End 2021 Financial Results and Corporate Update.
Palisade Bio Inc - Anticipates That Its Efforts for 2022 Will Largely Focus on Advancing Lb1148 in the Clinic.
Palisade Bio - Plan to Initiate Phase 3 Study for Accelerating Return of Bowel Function in H1 of 2022, for First Patient to Be Enrolled in H2 of 2022.
Palisade Bio - to Commence Enrolling Patients Under Amended Protocol During H1 2022 for Phase 2 Study on Prevention of Post-operative Adhesions.
Palisade Bio Inc - Cash and Cash Equivalents As of December 31, 2021, Were $10.5 Million, While Outstanding Debt Was Less Than $0.1 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.